This comprehensive program is for the design, synthesis, and evaluation of new retinoids as potential chemopreventive agents. To select, from all that are prepared, retinoids with the greatest chemopreventive potential, the compounds will be evaluated initially in biochemical and organ culture systems and in systems designed to measure their immunological properties. Those selected will be tested in vivo for their effect in preventing skin papillomas, bladder cancer, and mammary carcinomas. For compounds having considerable activity in one or more of these systems, pharmacological and toxicological studies will be performed. The results of these studies, with observations on the structure-activity relationships, will be used to guide the synthesis program in the design of new compounds and to select candidates for clinical investigation. Research projects, each relating to the mechanism of action of retinoids, concern (a) early events associated with the binding and uptake of retinoids and with tumor promotion; (b) the function of retinoic acid binding proteins; (c) the relationship between disposition and chemopreventive activity of retinoids; (d) evaluation of the effects of retinoids on immune function; and (e) synthesis of new retinoids having potential chemopreventive activity, but little toxicity. The development of new, more effective, and less toxic retinoids would offer hope of therapy to those who have been or will be exposed to substantial quantities of carcinogens and to others determined to be at high risk for cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA034968-06
Application #
3093604
Study Section
Cancer Therapeutics Program Project Review Committee (CTR)
Project Start
1984-08-01
Project End
1991-11-30
Budget Start
1990-05-01
Budget End
1991-11-30
Support Year
6
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Southern Research Institute
Department
Type
DUNS #
006900526
City
Birmingham
State
AL
Country
United States
Zip Code
35205
Shealy, Y Fulmer; Riordan, James M; Frye, Jerry L et al. (2003) Inhibition of papilloma formation by analogues of 7,8-dihydroretinoic acid. J Med Chem 46:1931-9
Shealy, Y F; Hill, D L; Sani, B P et al. (1998) Anhydroretinol, a retinoid active in preventing mammary cancer induced in rats by N-methyl-N-nitrosourea. Oncol Rep 5:857-60
Muccio, D D; Brouillette, W J; Breitman, T R et al. (1998) Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias. J Med Chem 41:1679-87
Shealy, Y F; Frye, J L; Hill, D L et al. (1998) Retinyl substituted-benzyl ethers. Inhibition of mammary carcinogenesis by retinyl 3,4,5-trimethoxybenzyl ether (RTMBE). Anticancer Drug Des 13:159-82
Shih, T W; Lin, T H; Shealy, Y F et al. (1997) Nonenzymatic isomerization of 9-cis-retinoic acid catalyzed by sulfhydryl compounds. Drug Metab Dispos 25:27-32
Sani, B P; Venepally, P R; Levin, A A (1997) Didehydroretinoic acid: retinoid receptor-mediated transcriptional activation and binding properties. Biochem Pharmacol 53:1049-53
Shimada, T; Ross, A C; Muccio, D D et al. (1997) Regulation of hepatic lecithin:retinol acyltransferase activity by retinoic acid receptor-selective retinoids. Arch Biochem Biophys 344:220-7
Shealy, Y F; Frye, J L; Riordan, J M et al. (1997) Retinyl ethers as cancer chemopreventive agents. Suppression of mammary cancer. Anticancer Drug Des 12:15-33
Sani, B P; Zhang, X; Hill, D L et al. (1996) Retinyl methyl ether: binding to transport proteins and effect on transcriptional regulation. Biochem Biophys Res Commun 223:293-8
Lin, T H; Rogers, T S; Hill, D L et al. (1996) Murine toxicology and pharmacology of UAB-8, a conformationally constrained analog of retinoic acid. Toxicol Appl Pharmacol 139:310-6

Showing the most recent 10 out of 60 publications